OBJECTIVE： To observe clinical efficacy and safety of tegafur combined with three dimensional conformal radiotherapy for advanced esophageal carcinoma. METHODS： Totally 88 cases of advanced esophageal carcinoma admitted into Xuchang central hospital during Aug. 2013-Mar. 2016 were selected and divided into control group and observation group according to random number table， with 44 cases in each group. On the basis of anti-inflammatory， relieving asthma and other symptomatic treatment， two groups accepted three dimensional conformal radiotherapy. Control group was given fluorouracil 80 mg/m2，ivgtt，d1+nadeplatin 70 mg/m2，ivgtt，d1-d5. Observation group was given Tegafur capsules 60 mg，bid， continuous use 5 days， rest for 2 days. A treatment course lasted for 3 weeks， and they received 3 courses of treatment. Clinical efficacies of 2 groups were observed as well as serum inflammatory factors （TNF-α， IL-6， IL-8）， lab indexes （VEGF， CA125， CA199， CEA）， QLQ-C30 scores before and after treatment. The occurrence of ADR was recorded in 2 groups. RESULTS： The total response rate of observation group was 88.64％， which was significantly higher than 68.18％， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in serum inflammatory factor levels， lab index levels and QLQ-C30 scores between 2 groups （P＞0.05）. After treatment， serum inflammatory factor levels and lab index levels of 2 groups were significantly decreased， while QLQ-C30 scores were decreased significantly； the observation group was significantly better than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Tegafur combined with three dimensional conformal radiotherapy shows good therapeutic efficacy for advanced esophageal carcinoma， can significantly reduce serum inflammatory factor levels and lab index levels and improve life quality but do not increase the occurrence of ADR.